{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:03:14Z","timestamp":1791270194595,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,10,16]],"date-time":"2001-10-16T00:00:00Z","timestamp":1003190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"State of Bavaria","award":["KKF, project 8756159"],"award-info":[{"award-number":["KKF, project 8756159"]}]},{"name":"Berliner Krebsgesellschaft, Interdisciplinary Research Project: Molecular Biology and Clinic of Breast and Ovarian Cancers"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2002,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Intrinsic or acquired resistance to chemotherapy is responsible for failure of current treatment regimens in breast cancer patients. The Y\u2010box protein\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    regulates expression of the P\u2010glycoprotein gene\n                    <jats:italic>mdr1<\/jats:italic>\n                    , which plays a major role in the development of a multidrug\u2010resistant tumor phenotype. In human breast cancer, overexpression and nuclear localization of\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    is associated with upregulation of P\u2010glycoprotein. In our pilot study, we analyzed the clinical relevance of\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    expression in breast cancer (\n                    <jats:italic>n<\/jats:italic>\n                    = 83) after a median follow\u2010up of 61 months and compared it with tumor\u2010biologic factors already used for clinical risk\u2010group discrimination,\n                    <jats:italic>i.e.<\/jats:italic>\n                    , HER2, urokinase\u2010type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI\u20101). High\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    expression in tumor tissue and surrounding benign breast epithelial cells was significantly associated with poor patient outcome. In patients who received postoperative chemotherapy, the 5\u2010year relapse rate was 66% in patients with high\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    expression. In contrast, in patients with low\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    expressions, no relapse has been observed so far.\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    expression thus indicates clinical drug resistance in breast cancer. Moreover,\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    correlates with breast cancer aggressiveness: in patients not treated with postoperative chemotherapy, those with low\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    expression are still free of disease, whereas the 5\u2010year relapse rate in those with high\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    was 30%. There was no significant correlation between\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    expression and either HER2 expression or uPA and PAI\u20101 levels. Risk\u2010group assessment achieved by\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    differed significantly from that by HER2 or uPA\/PAI\u20101. In conclusion,\n                    <jats:italic>YB\u20101<\/jats:italic>\n                    demonstrated prognostic and predictive significance in breast cancer by identifying high\u2010risk patients in both the presence and absence of postoperative chemotherapy, independent of tumor\u2010biologic factors currently available for clinical decision making. \u00a9 2001 Wiley\u2010Liss, Inc.\n                  <\/jats:p>","DOI":"10.1002\/ijc.1610","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T18:13:08Z","timestamp":1030299188000},"page":"278-282","source":"Crossref","is-referenced-by-count":149,"title":["Y\u2010box factor YB\u20101 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI\u20101"],"prefix":"10.1002","volume":"97","author":[{"given":"Martin","family":"Janz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peer","family":"Dettmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"J\u00fcrchott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Dieter","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0497-447"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.62.070193.002125"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.13.902"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/bies.950160407"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/bies.950170104"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.49.32957"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10157-5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/172460080001500114"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006118828278"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1994.1119"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690373"},{"key":"e_1_2_6_13_2","first-page":"4257","article-title":"Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas","volume":"19","author":"Lebeau A","year":"1999","journal-title":"Anticancer Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006449931921"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90426-X"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8924(98)01300-2"},{"key":"e_1_2_6_17_2","first-page":"4224","article-title":"Role of the human Y box\u2010binding protein YB\u20101 in cellular sensitivity to the DNA\u2010damaging agents cisplatin, mitomycin C, and ultraviolet light","volume":"56","author":"Ohga T","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511233332111"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<732::AID-IJC6>3.0.CO;2-#"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.14.10.1236"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/22.11.2036"},{"key":"e_1_2_6_23_2","first-page":"2273","article-title":"Nuclear expression of YB\u20101 protein correlates with P\u2010glycoprotein expression in human osteosarcoma","volume":"4","author":"Oda Y","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1055"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(00)00684-6"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.24.1991"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.12.913"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3058"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00307-5"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.1610","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.1610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T07:41:54Z","timestamp":1696837314000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.1610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,27]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,1,20]]}},"alternative-id":["10.1002\/ijc.1610"],"URL":"https:\/\/doi.org\/10.1002\/ijc.1610","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12,27]]}}}